Long Acting rFactor lX: Interim Phase III data

Interim data from the open-label, international Phase III B-YOND extension trial in 116 patients with severe hemophilia B showed that no inhibitors have been reported with treatment of Alprolix. Patients in B-YOND received 1 of 3 prophylactic dosing options of Alprolix: 20-100 IU/kg Alprolix once weekly (weekly prophylaxis); 100

Read the full 496 word article

How to gain access

Continue reading with a
two-week free trial.